TYRA-300 is under clinical development by Tyra Biosciences and currently in Phase II for Metastatic Transitional (Urothelial) Tract Cancer. According to GlobalData, Phase II drugs for Metastatic Transitional (Urothelial) Tract Cancer have a 46% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how TYRA-300’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TYRA-300 overview
TYRA-300 is under development for the treatment of metastatic urothelial carcinoma of the bladder and urinary tract, solid tumors and achondroplasia. The drug candidate acts by targeting fibroblast growth factor (FGF) receptor 3. It is being developed based on SNAP platform. It is administered by oral route.
Tyra Biosciences overview
Tyra Biosciences (Tyra) is a precision oncology company. It design and develop cancer drugs. It is investigating Tyra-300, an FGFR3 (fibroblast growth factor receptor 3) inhibitor targeting bladder and solid tumors. The company is also evaluating FGFR2 small molecule inhibitor for the treatment of bile duct and solid tumors; FGFR3 (ACH) program against achondroplasia; an RET-specific inhibitor for lung and thyroid cancer; and FGFR4-specific inhibitor liver and solid tumors. It utilizes SNAP, a proprietary in-house discovery engine to discover and develop molecular structures for cancer. Tyra is headquartered in Carlsbad, California, the US.
For a complete picture of TYRA-300’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
Smarter leaders trust GlobalData
Premium Insights Likelihood of Approval and Phase Transition Success Rate Model - TYRA-300 in Metastatic Transitional (Urothelial) Tract Cancer
Premium Insights
The gold standard of business intelligence.
